Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 22, 2025Open Access

Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson’s Disease: A Brief Review

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLUIS FERNANDO SIQUEIRA RIBEIROLMLarissa Emika MassudaVGVanessa Silva Gontijo

Discussion

Loading...

Member takes

Overview

Brief review highlights monoamine oxidase's role in parkinson's disease, suggesting potential drug interventions.

Key Points

  • Monoamine oxidase inhibitors may improve treatment outcomes for patients with parkinson's disease, a neurodegenerative disorder.
  • Evidence indicates that targeting monoamine oxidase-B could be key in addressing dopamine deficits in parkinson's disease.
  • Recent literature reviews suggest advancements in medicinal chemistry lead to promising drug candidates to inhibit monoamine oxidase.
  • Research highlights a complex interplay of biochemical pathways in parkinson's disease that monoamine oxidase inhibitors may address.

Cite This Study

RIBEIRO et al. (2025) studied this question.

synapsesocial.com/papers/68af7b187567bf4f94ff29fehttps://doi.org/10.20944/preprints202508.1652.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-target monoamine oxidase-B (MAO-B) inhibitors in the treatment of Parkinson’s disease2025 · 3 citations
  2. 2Unraveling Parkinson’s disease: from dopaminergic dysfunction to novel therapeutic targets2025 · 2 citations
  3. 3Design, synthesis, investigation, and biological activity assessments of n -allyl-2-(benzylidene) hydrazine-1-carbothioamide derivatives as monoamine oxidase-b inhibitor agents2025
  4. 4Target-based Virtual Screening of Natural Compounds as Promising Anti-Parkinson’s Agents2025
  5. 5Update on the Present and Future Pharmacologic Treatment of Parkinson’s Disease2025 · 6 citations